Market Overview

Benzinga's Daily Biotech Pulse: Melinta, Ardelyx Pull Back On Offerings, Insys Awaits FDA Verdict

Share:
Benzinga's Daily Biotech Pulse: Melinta, Ardelyx Pull Back On Offerings, Insys Awaits FDA Verdict
Related IBB
The Daily Biotech Pulse: Mallinckrodt FDA Verdict, European Cheer For Bristol-Myers Squibb, Morphosys Clinches Licensing Deal
The Daily Biotech Pulse: Mallinckrodt Faces FDA Panel, Reshape's Earnings, Vapotherm To Debut
The Market's Brown Earth Dog Meets The Skeletal Bull (TalkMarkets)
Related AMGN
Attention Biotech Investors: Mark Your Calendar For These November PDUFA Dates
The Daily Biotech Pulse: KemPharm, FDA Nod For Merck, Clovis Q3 Miss, 3 Stocks To Debut
Cancer Research Highlight: RedHill Biopharma Sets Up Continued Invasion Into Cancer (Seeking Alpha)

Here's a roundup of top developments in the biotech space over the last 24 hours.

Scaling the Peaks

(Biotech Stocks Hitting 52-week highs on May 21)

  • AstraZeneca plc (ADR) (NYSE: AZN) (FDA approved its hyperkalaemia drug Lokelma)
  • Atara Biotherapeutics Inc (NASDAQ: ATRA)
  • Bio-Rad Laboratories, Inc. (NYSE: BIO)
  • Boston Scientific Corporation (NYSE: BSX)
  • Haemonetics Corporation (NYSE: HAE)
  • Inspire Medical Systems Inc (NYSE: INSP)
  • Merit Medical Systems, Inc. (NASDAQ: MMSI)
  • T2 Biosystems Inc (NASDAQ: TTOO)

Down In The Dumps

(Biotech Stocks Hitting 52-week lows on May 21)

  • Altimmune Inc (NASDAQ: ALT)
  • Calithera Biosciences Inc (NASDAQ: CALA)
  • Celgene Corporation (NASDAQ: CELG)
  • Edge Therapeutics Inc (NASDAQ: EDGE)
  • Immune Pharmaceuticals Inc (NASDAQ: IMNP)
  • Jounce Therapeutics Inc (NASDAQ: JNCE)
  • Mustang Bio Inc (NASDAQ: MBIO)
  • Stellar Biotechnologies Inc (NASDAQ: SBOT)

Related Link: The Week Ahead In Biotech: PDUFA Dates, IPOs And More

Stocks In Focus

Amgen's Osteoporosis Drug Approved

Amgen, Inc. (NASDAQ: AMGN) announced that the FDA approved its Prolia – chemically denosumab – to treat glucocorticoid-induced osteoporosis in men and women at high risk of fracture, or patients who have failed, or are intolerant to other available osteoporosis therapy.

The company said the approval is based on a late-stage study that showed patients who received Prolia had greater gains in bone mineral density relative to those who received active comparator.

Melinta Announces Stock Offering

Melinta Therapeutics, Inc. (NASDAQ: MLNT) announced the commencement of a common stock offering to raise aggregate proceeds of $75 million. All the stocks sold in the offering are sold by the company.

Melinta slumped 8.9 percent to $6.65 after hours.

Ardelyx to Offer Common Stock, Inks Loan Agreement

Ardelyx Inc (NASDAQ: ARDX) said it has commenced an offering of upto $50 million worth of shares, with all shares being offered by the company. Separately, the company said it has reached a loan agreement with Solar Capital and Bridge Bank to raise $50 million in loan.

The stock shed 8.85 percent to $5.15 after hours.

On The Radar

The FDA will announce its decision on Insys Therapeutics Inc (NASDAQ: INSY)'s NDA for buprenorphine to treat moderate-to-severe post-operative pain after bunionectomy.

Catalyst Biosciences Inc (NASDAQ: CBIO) is set to present Phase 1/2 data for its hemophilia B treatment combo CB2679d/ISU304 at the World Federation of Hemophilia (WFH) World Congress.

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is scheduled to present Phase 2 data on its hemophilia B treatment candidate valoctocogene roxaparvovec at the WFH.

Posted-In: Biotech News FDA Top Stories Pre-Market Outlook Trading Ideas Best of Benzinga

 

Related Articles (AMGN + ALT)

View Comments and Join the Discussion!

25 Stocks Moving In Tuesday's Pre-Market Session

Jim Cramer Weighs In On Royal Caribbean Cruises, Allergan And More